The Tempest

Tempest Therapeutics is a Nasdaq-listed clinical-stage oncology biotechnology company developing therapies intended to combine tumor-targeted and immune-mediated mechanisms. Historically the company has focused on first-in-class oral small molecules, led by amezalpat (TPST-1120), a PPAR-alpha antagonist that the company describes as Phase 3-ready for first-line hepatocellular carcinoma, and TPST-1495, a dual EP2/EP4 antagonist in clinical development. In late 2025 and early 2026, Tempest broadened its pipeline through the acquisition of dual-targeting CAR-T assets from Factor Bioscience, adding TPST-2003 for relapsed/refractory multiple myeloma and extramedullary disease. The company is headquartered in Brisbane, California and is repositioning from a small-molecule oncology company into a broader oncology platform spanning both targeted therapeutics and cell therapy assets. Its business strategy includes advancing late-stage liver cancer development, selectively progressing TPST-1495, and partnering TPST-2003 for planned U.S. registrational work.